NCT05942222View on ClinicalTrials.gov

A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Chronic Rhinosinusitis With Nasal PolypsAsthma; EosinophilicEosinophilia
Interventions
BIOLOGICAL

dupilumab

Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.

BIOLOGICAL

mepolizumab

Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.

Trial Locations (9)

2100

Rigshospitalet, Copenhagen

3400

Nordsjællands Hospital, Hillerød

4600

Sjællands Universitetshospital Køge, Køge

5000

Odense Universitetshospital, Odense

6700

Sydvestjysk Sygehus Esbjerg, Esbjerg

7100

Sygehus Lillebælt Vejle, Vejle

7400

Regionshospitalet Gødstrup, Herning

8200

Aarhus Universitetshospital Skejby, Aarhus

9000

Aalborg Universitetssygehus Syd, Aalborg

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER